Friday, October 20, 2017

Integrated BioSci Investing: CAR-T FDA Approved And Promising Developments


  • CAR-TCR received FDA approval for the treatment of non-Hodgkin lymphoma.
  • Kite, Exelixis, and Spectrum are delivering stellar returns for subscribers.
  • We intend to increase the forecasting of both clinical and regulatory catalysts.
  • Integrated BioSci Investing portfolio is yielding an overall robust return.

The biotech sector is highly promising with merger and acquisition to boost for stellar profits. In the past 52-weeks, Kite Pharma (NASDAQ:KITE) was acquired by Gilead Sciences Inc (NASDAQ:GILD) for $11.9B (on Aug. 28, 2017). This catapulted our portfolio’s profits on Kite to 82%. As this story is playing out, the FDA approved CAR-TCR as the treatment for non-Hodgkin lymphoma (on Oct. 18, 2017). The stellar news (for both patients and investors) gives further credence to our thesis on CAR-TCR (as a major breakthrough since the introduction of chemotherapy, half a decade prior).

As we anticipated, our Integrated BioSci Investing portfolio has several big winners, mostly average performers, and a few losers. Overall, we herald a significant winning record. We are committed to continuing our quality service and strong track record of performance (in servicing our partners and patients) in the future.

Looking forward, we’re entertaining the prospects of increasing our focus on growth catalysts and binary events. This pertains to the forecasting outcomes for trial data and regulatory approvals (an area, in which we have a robust track record to this date). We believe that traders will enjoy that increasing coverage of catalytic events (to give you an advantage in the trade).

Along with another expert (Decision Analytics), our data forecasting on the poziotinib phase 2 trial (studying its indication in the exon 20 mutated non-small cell lung cancers) helped Spectrum Pharmaceuticals (NASDAQ:SPPI) investors gained 36% in one day. Poziotinib demonstrated stellar efficacy and safety in treating the aforesaid dreaded cancers (due to its stellar design, that leverages on overcoming the steric hindrance as well as the attacking of multiple cancer targets like Cabozantinib of Exelixis (NASDAQ:EXEL).

Success asides, we are open about our mistakes (as we take responsibility and seek quality improvements). We addressed our shortcoming with Versartis (NASDAQ:VSAR) in a Marketplace article. In response, we conducted extremely thorough research on the long-acting growth hormone market. And, we gained new insight on the potential innovation of a novel growth hormone that can trump Genotropin. We’ll share the results with other experts (and subscribers in our marketplace), who are interested.

As a reminder, the core of our service centers around the finding of stellar bioscience stocks (and in unlocking their value for investors) for you to hold for the long haul. We partnered with Seeking Alpha to do all of the heavy liftings for you. Even if you are a novice investor (or a seasoned investment professional, new to the bioscience sector), you can model our portfolio for potentially lucrative profits.

As you potential business partner, we align our interests with yours. We seek to increase wealth for you all. Moreover, we work tirelessly, in assisting firms that are innovating and commercializing life-saving therapeutics to patients (for them to deliver hopes in seemingly hopeless situations). Furthermore, we intend to build wealth via this portfolio and service along with you for the ultra long haul. And, we seek to build capital (so that one day we can have the means to innovate our own life-saving drugs for patients).

On the behalf of Integrated BioSci Investing market research, we wish you much health and fortune. Thank you all.

Author’s Note: We briefly mentioned a few key performers in this article. In contrast, we conduct in-depth quarterly portfolio performance in our marketplace research. Articles published in the marketplace are higher level thinking. If you haven’t done so, please click the orange follows button to get our latest insight. And, to reap the full benefits of our service (in potentially earning stellar profits from binary events trading), you should consider our marketplace service.